Dupilumab Nears €10 Billion in Sales for First Three Quarters; Changchun High-Tech Reports RMB 10.387 Billion Revenue in First Nine Months of 2024
Sanofi
Pharmaceutical Manufacturer
CHANGCHUN HIGH-TECH
Pharmaceutical R&D Developer
Haihe Biopharma
Developer of Innovative Anti-Tumor Drugs
Bioperfectus Technologies
Molecular Diagnostics Product Developer
Huadao Biopharma
Developer and Manufacturer of Cell-Based Immunotherapy Drugs
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
Global pharmaceutical companies successively announce their Q3 reports.
On October 25, Sanofi announced its Q3 2024 financial report.
During the reporting period, the company's total revenue was 13.438 billion euros, a year-on-year increase of 15.7%. Of this, revenue from China amounted to 757 million euros, marking a year-on-year growth of 3.6%.
Dupilumab, as Sanofi's flagship product, achieved sales of 3.476 billion euros in the third quarter, representing a year-on-year increase of 23.8%. As of 2024, the total sales of Dupilumab have reached 9.614 billion euros.
On the same day, CHANGCHUN HIGH-TECH released its Q3 report. During the reporting period, the company's revenue was 3.749 billion yuan, with a net profit of 1.103 billion yuan; for the first three quarters, the company's revenue reached 10.387 billion yuan, with a net profit of 2.840 billion yuan.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) CanSinoBIO Collaborates with Malaysia's NIBM to Develop mRNA Multivalent Influenza Vaccine
On October 25, CanSinoBIO announced on its official WeChat account that it has recently further established a collaboration with the Malaysian National Biotechnology Institute. Both parties will work together to advance the development of an mRNA multivalent influenza vaccine, contributing to global influenza prevention and control.
2) Shenyang Sunshine Pharmaceutical Co., Ltd. introduces oral paclitaxel solution
On October 24, HaiHe Biopharma and 3SBio jointly announced that Shenyang 3SBio, a subsidiary of 3SBio, has obtained the exclusive commercialization rights for the product Paclitaxel Oral Solution from Nomax Pharmaceuticals, a subsidiary of HaiHe Biopharma, in mainland China and Hong Kong.
/ 02 /
Capital Information
1) Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Achieves Net Profit of Approximately 86.47 Million Yuan in the First Three Quarters
On October 25, Fudan-Zhangjiang released its third-quarter report. For the nine months ended September 30, 2024, the group reported revenue of RMB 549 million, a year-on-year decrease of 22.47%; net profit was RMB 86.4686 million, a year-on-year decrease of 3.81%.
2) CHANGCHUN HIGH-TECH Achieves Revenue of 10.3 Billion Yuan in the First Three Quarters
On October 25, CHANGCHUN HIGH-TECH released its Q3 report. During the reporting period, the company's revenue was 3.749 billion yuan, with a net profit of 1.103 billion yuan; for the first three quarters, the company's revenue reached 10.387 billion yuan, and the net profit was 2.840 billion yuan.
3) Bioperfectus Technologies' Net Profit in the First Three Quarters Increased by 115.40% Year-on-Year
On October 25, Bioperfectus Technologies released its Q3 report. In the first three quarters, the company achieved revenue of 268 million yuan, a year-on-year decrease of 3.02%; net profit was 27.1147 million yuan, a year-on-year increase of 115.40%. However, in the third quarter, the company reported a net loss of 2.1259 million yuan.
/ 03 /
Pharmaceutical News
1) Prokairong MSCohi-O Lens Receives Clinical Approval
On October 25, according to the CDE official website, Guangdong Prokairong Biomedical Technology Co., Ltd.'s MSCohi-O lens received clinical approval and is intended for the treatment of chronic ocular graft-versus-host disease.
2) HuaDao CAR-Tcell HD004 Receives Clinical Approval
On October 25, according to the CDE official website, HuaDao CAR-Tcell's HD004 received clinical approval for use in advanced solid tumors with CLDN18.2-positive expression accompanied by malignant ascites.
3) CSPC Group's SYS6020 Injection Receives Clinical Approval
On October 25, according to the CDE official website, SYS6020 Injection from CSPC Group received clinical approval and is intended for the treatment of refractory generalized myasthenia gravis.
4) Kelun Botai's Injection of Lukansatuzumab Receives Clinical Approval
On October 25, according to the CDE official website, Kelun-Biotech's injection of Lukansatuzumab received clinical approval for use in adult patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer who have failed treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI).
5) Shijian Biotech's Recombinant Humanized Anti-Trop2 Monoclonal Antibody-SN38 Conjugate Granted Breakthrough Therapy Designation
On October 25, according to the CDE official website, Shijian Biotech's recombinant humanized anti-Trop2 monoclonal antibody-SN38 conjugate is proposed to receive breakthrough therapy designation for previously untreated, inoperable locally advanced, recurrent, or metastatic PD-L1-negative triple-negative breast cancer.
/ 04 /
Instrument Tracking
1) JiaKai Medical's Brain EEG Depth Monitor Launch Rejected
On October 25, according to the NMPA website, JiaKai Medical's deep brain monitoring instrument for consciousness received a non-registration approval.
2) BenSheng Electronics Non-Invasive Cardiac Output Monitor Rejected for Market Entry
On October 25, according to the NMPA website, BenSheng Electronics' non-invasive cardiac output monitor was rejected for market approval.
3) AccuRadi Surgical Navigation and Positioning System for Spinal Surgery Receives Registration Approval
On October 25, according to the NMPA website, ZhuoXin Medical's spinal surgery navigation and positioning system obtained registration approval.
4) Peninsula Medical Picosecond Nd:YAG Laser Treatment Device Receives Registration Approval
On October 25, according to the NMPA website, Peninsula Medical's picosecond Nd:YAG laser treatment device obtained registration approval.
5) Guichuang Medical Thrombus Aspiration Negative Pressure Attraction Pump Receives Registration Approval
On October 25, according to the NMPA website, GuiChuang Medical's thrombus aspiration negative pressure suction pump obtained registration approval.
6) Mindray Bio-Medical Ultrasound Diagnostic System Receives Registration Approval
On October 25, according to the NMPA website, Mindray Bio-Medical's ultrasound diagnostic system obtained registration approval.
7) AmoyDx Human IDH1 Gene Mutation Detection Kit (Fluorescence PCR Method) Obtains Registration Certificate
On October 25, according to the NMPA website, AmoyDx's Human IDH1 Gene Mutation Detection Kit (Fluorescence PCR Method) received registration approval.
/ 05 /
Digital Healthcare Daily
1) United Imaging Intelligent Breast X-ray Image Auxiliary Detection Software Obtains Registration Certificate
On October 25, according to the NMPA website, United Imaging Intelligence's mammography image-assisted detection software received registration approval.
/ 06 /
Overseas Pharmaceutical News
1) Dupilumab’s Sales in the First Three Quarters Approach 10 Billion Euros
On October 25, Sanofi announced its third-quarter report for 2024. During the reporting period, the company's total revenue was 13.438 billion euros, a year-on-year increase of 15.7%. Of this, revenue from China amounted to 757 million euros, marking a year-on-year increase of 3.6%. Dupilumab, Sanofi’s flagship product, achieved sales of 3.476 billion euros in Q3, reflecting a year-on-year growth of 23.8%. From the beginning of 2024 to now, the total sales of Dupilumab have reached 9.614 billion euros.
PS: Welcome to scan the QR code below to add the WeChat ID of AminoGenius for communication.
